In a groundbreaking move, the FDA has given the green light to the first gene therapy aimed at addressing genetic hearing loss, marking a significant advancement in medical treatment for those affected by inherited deafness. Regeneron, the company behind this therapy, announced that it will also offer the treatment for free to eligible patients. This innovative therapy has shown impressive results, restoring hearing in 90% of participants during clinical trials, and long-lasting effects have been demonstrated, with benefits persisting for over two years. The approval represents a landmark moment in the treatment of congenital deafness, providing hope to children and families struggling with rare forms of hearing loss.